Mara Bacchiani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mara Bacchiani has a total of 88 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Minervini
Department of Experimental and Clinical Medicine, University of Florence, 50121 Firenze, Italy
5 shared publications - Andrea Mari
University of Florence, Italy
3 shared publications - Anna Cadenar
Department of Experimental and Clinical Medicine, University of Florence, 50121 Firenze, Italy
3 shared publications - Antonio Andrea Grosso
Department of Experimental and Clinical Medicine, University of Florence, 50121 Firenze, Italy
3 shared publications - Fabrizio Di Maida
Unit of Oncologic Minimally-Invasive Urology and Andrology, Department of Experimental and Clinical Medicine, University of Florence, Careggi Hospital, 50134 Florence, Italy
3 shared publications - Vincenzo Li Marzi
Department of Medical, Surgical and Neurological Science, University of Siena, Siena, Italy
3 shared publications
Latest Publications
- Open Access
- 8 December 2025
- Published by Springer Nature in La radiologia medica
- Vol. 131 (5) , 889
Correction: Prostatic artery embolization with glue for benign prostatic hyperplasia in elderly patients: three-year results
- 8 December 2025
- Published by Springer Nature in La radiologia medica
- Vol. 131 (5) , 889
Open AccessCorrection: Prostatic artery embolization with glue for benign prostatic hyperplasia in elderly patients: three-year results
- Open Access
- 18 November 2025
- Published by Springer Nature in La radiologia medica
- Vol. 131 (3) , 531-540
Prostatic artery embolization with glue for benign prostatic hyperplasia in elderly patients: three-year results
Purpose: To evaluate the clinical efficacy and safety of prostatic artery embolization (PAE) using glue (n-butyl cyanoacrylate, NBCA) in patients with benign prostatic hyperplasia (BPH) presenting with lower urinary tract symptoms (LUTS) due to obstruction or chronic urinary retention managed with an indwelling catheter (IUC). Material and Methods: A total of 101 patients (median age 79 years) were included, of whom 67 had LUTS and 34 had an IUC. All were treated with PAE with glue between 2021 and 2024. Clinical success was defined as either a ≥ 25% reduction in the International Prostate Symptom Score (IPSS) and a ≥ 3-point improvement in the quality of life (QoL) score or stable catheter removal. Results: Technical success was achieved in 100% of cases, with bilateral embolization in 93% of patients. Among symptomatic patients, clinical success was observed in 92.5%, with a reduction in IPSS from 25.3 ± 8.1 to 15.3 ± 7.8 and in QoL from 4.5 ± 1.1 to 2.3 ± 1.4 at 36 months ( p < 0.001). Mean prostate volume decreased by 37.6%. In patients with an IUC, 73.5% resumed spontaneous voiding within an average of 29 days. All complications (13.9%) were minor and managed conservatively. Conclusion: Embolization with acrylic glue is a safe and effective minimally invasive alternative to surgery for BPH, with sustained long-term results. It is particularly suitable for elderly patients with comorbidities or those unfit for surgery presenting with LUTS or chronic urinary retention.
- 18 November 2025
- Published by Springer Nature in La radiologia medica
- Vol. 131 (3) , 531-540
Open AccessProstatic artery embolization with glue for benign prostatic hyperplasia in elderly patients: three-year results
Purpose: To evaluate the clinical efficacy and safety of prostatic artery embolization (PAE) using glue (n-butyl cyanoacrylate, NBCA) in patients with benign prostatic hyperplasia (BPH) presenting with lower urinary tract symptoms (LUTS) due to obstruction or chronic urinary retention managed with an indwelling catheter (IUC). Material and Methods: A total of 101 patients (median age 79 years) were included, of whom 67 had LUTS and 34 had an IUC. All were treated with PAE with glue between 2021 and 2024. Clinical success was defined as either a ≥ 25% reduction in the International Prostate Symptom Score (IPSS) and a ≥ 3-point improvement in the quality of life (QoL) score or stable catheter removal. Results: Technical success was achieved in 100% of cases, with bilateral embolization in 93% of patients. Among symptomatic patients, clinical success was observed in 92.5%, with a reduction in IPSS from 25.3 ± 8.1 to 15.3 ± 7.8 and in QoL from 4.5 ± 1.1 to 2.3 ± 1.4 at 36 months ( p < 0.001). Mean prostate volume decreased by 37.6%. In patients with an IUC, 73.5% resumed spontaneous voiding within an average of 29 days. All complications (13.9%) were minor and managed conservatively. Conclusion: Embolization with acrylic glue is a safe and effective minimally invasive alternative to surgery for BPH, with sustained long-term results. It is particularly suitable for elderly patients with comorbidities or those unfit for surgery presenting with LUTS or chronic urinary retention.
- 19 May 2025
- Published by Wiley in Neurourology and Urodynamics
A Novel Scoring System to Assess Continence Quality Outcomes of Orthotopic Ileal Neobladders After Open and Robot‐Assisted Radical Cystectomy: The Urodynamic Trifecta
Introduction: A comprehensive scoring system for standardizing quality of functional outcomes of orthotopic ileal neobladders (OINs) is still unavailable. In this study we propose a novel trifecta for both open and robot‐assisted radical cystectomy conceived on urodynamic parameters that summarize OINs functional outcomes regardless of the surgical technique used and predicts continence status.Materials & Methods: Between June 2017 and May 2023 two prospective, institutional review board approved, radical cystectomy datasets were matched and queried for “OINs” “and “urodynamic evaluation” (n = 149). Urodynamic assessment was performed between 6 and 9 months after surgery. Baseline data and complete urodynamic profile including uroflowmetry, cystometry, compliance, presence of residual peristaltic activity, abdominal leak point pressures (ALPP) and daytime and night‐time continence were reported. Descriptive analyses were used. Frequencies and proportions were reported for categorical variables while medians and interquartile ranges (IQRs) were reported for continuously coded variables. Trifecta was defined as the coexistence of: cystometric capacity ≥ 250 cc; neobladder compliance ≥ 35 cmH20; negative Valsalva and abdominal leak point pressure testing. Simultaneous achievement of only two of the presented criteria was considered a suboptimal result. Logistic regression analyses were built to identify predictors of daytime and night‐time urinary continence. For all analyses, a two‐sided p < 0.05 was considered significant.Results: Overall, at a median follow‐up of 25 months (IQR 16–37), 149 patients achieved a complete urodynamic evaluation. In the current series, the complete trifecta rate was 40.2% while a suboptimal trifecta achievement was observed in 35.6% of patients. On multivariable analysis, complete trifecta achievement was the only independent predictor of daytime (OR 7.29, 95% CI 2.05–25.9) and night‐time (OR 8.13; 95% CI 2.94–22.4) urinary continence, respectively (each p < 0.003). A complete UDM‐T at urodynamic testing was associated with a day‐time continence, night‐time continence, and complete dry status rates of 93.2%, 83.1%, and 79.7%, respectively.Conclusion: This novel urodynamic trifecta for OINs is based on standardized parameters and seems to be predictor of either daytime or night‐time urinary continence at a midterm follow‐up. Satisfactory continence outcomes may be also expected when a suboptimal trifecta rate is achieved.Clinical Trial Registration: Not applicable.
- 19 May 2025
- Published by Wiley in Neurourology and Urodynamics
A Novel Scoring System to Assess Continence Quality Outcomes of Orthotopic Ileal Neobladders After Open and Robot‐Assisted Radical Cystectomy: The Urodynamic Trifecta
Introduction: A comprehensive scoring system for standardizing quality of functional outcomes of orthotopic ileal neobladders (OINs) is still unavailable. In this study we propose a novel trifecta for both open and robot‐assisted radical cystectomy conceived on urodynamic parameters that summarize OINs functional outcomes regardless of the surgical technique used and predicts continence status.Materials & Methods: Between June 2017 and May 2023 two prospective, institutional review board approved, radical cystectomy datasets were matched and queried for “OINs” “and “urodynamic evaluation” (n = 149). Urodynamic assessment was performed between 6 and 9 months after surgery. Baseline data and complete urodynamic profile including uroflowmetry, cystometry, compliance, presence of residual peristaltic activity, abdominal leak point pressures (ALPP) and daytime and night‐time continence were reported. Descriptive analyses were used. Frequencies and proportions were reported for categorical variables while medians and interquartile ranges (IQRs) were reported for continuously coded variables. Trifecta was defined as the coexistence of: cystometric capacity ≥ 250 cc; neobladder compliance ≥ 35 cmH20; negative Valsalva and abdominal leak point pressure testing. Simultaneous achievement of only two of the presented criteria was considered a suboptimal result. Logistic regression analyses were built to identify predictors of daytime and night‐time urinary continence. For all analyses, a two‐sided p < 0.05 was considered significant.Results: Overall, at a median follow‐up of 25 months (IQR 16–37), 149 patients achieved a complete urodynamic evaluation. In the current series, the complete trifecta rate was 40.2% while a suboptimal trifecta achievement was observed in 35.6% of patients. On multivariable analysis, complete trifecta achievement was the only independent predictor of daytime (OR 7.29, 95% CI 2.05–25.9) and night‐time (OR 8.13; 95% CI 2.94–22.4) urinary continence, respectively (each p < 0.003). A complete UDM‐T at urodynamic testing was associated with a day‐time continence, night‐time continence, and complete dry status rates of 93.2%, 83.1%, and 79.7%, respectively.Conclusion: This novel urodynamic trifecta for OINs is based on standardized parameters and seems to be predictor of either daytime or night‐time urinary continence at a midterm follow‐up. Satisfactory continence outcomes may be also expected when a suboptimal trifecta rate is achieved.Clinical Trial Registration: Not applicable.
- Open Access
- 3 February 2025
- Published by Springer Nature in International Urology and Nephrology
- Vol. 57 (7) , 2157
Correction: Intravesical administration of highly concentrated hyaluronic acid and chondroitin sulfate as add‑on therapy for chemical cystitis induced by Bacillus Calmette–Guérin (BCG) immunotherapy
- 3 February 2025
- Published by Springer Nature in International Urology and Nephrology
- Vol. 57 (7) , 2157
Open AccessCorrection: Intravesical administration of highly concentrated hyaluronic acid and chondroitin sulfate as add‑on therapy for chemical cystitis induced by Bacillus Calmette–Guérin (BCG) immunotherapy
- 16 January 2025
- Published by Springer Nature in International Urology and Nephrology
- Vol. 57 (7) , 2033-2039
Intravesical administration of highly concentrated hyaluronic acid and chondroitin sulfate as add-on therapy for chemical cystitis induced by Bacillus Calmette–Guérin (BCG) immunotherapy
Purpose Intravesical (i) immunotherapy with Bacillus Calmette–Guérin (BCG) is the recommended treatment for patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) after complete tumor resection. Discontinuation or suspension of this therapy is often due to local side effects. Aim of the study was to evaluate the efficacy and safety of sequential intravesical instillations of combined hyaluronic acid (HA) and chondroitin sulfate (CS) in reducing local BCG toxicity and urinary symptoms. Methods This was a prospective, multicentric study. Patients underwent BCG intravesical administration after Transurethral Resection of Bladder Tumor (TURBT) for intermediate/high-risk NMIBC. Patients underwent to HA + CS instillations after every (i) BCG (Group A) were compared with a control group (Group B) that included patient underwent only to BCG instillations, during the maintenance period. 3-day voiding diary, the International Prostate Symptom Score (IPSS), IPSS quality-of-life index (IPSS-QoL), and VAS score (to evaluate bladder pain) were evaluated at baseline and at 1-, 3-, and 6-month follow- up. Results One hundred-eighteen patients were included (Group A: 63 patients, Group B: 55 patients). Mean value of IPSS, IPSS-QoL, and VAS score has significantly increase in Group A at 1-, 3-, and 6-month follow-up (p < 0.00). Group A showed also a significant improvement about irritative lower urinary symptoms (LUTS), which was maintained in the 6-month follow-up, as opposed to Group B that demonstrated a worsening in urinary symptoms during all follow-up (p < 0.00). No local or major side effects were reported during or after treatment. Conclusion This study demonstrated that adding (i) HA + CS significantly reduces storage symptoms, pelvic pain, and day-time urinary frequency in patients with BCG-induced chemical cystitis. This therapy could therefore improve patient adherence, ensuring better adherence and lower drop-out rates.
- 16 January 2025
- Published by Springer Nature in International Urology and Nephrology
- Vol. 57 (7) , 2033-2039
Intravesical administration of highly concentrated hyaluronic acid and chondroitin sulfate as add-on therapy for chemical cystitis induced by Bacillus Calmette–Guérin (BCG) immunotherapy
Purpose Intravesical (i) immunotherapy with Bacillus Calmette–Guérin (BCG) is the recommended treatment for patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) after complete tumor resection. Discontinuation or suspension of this therapy is often due to local side effects. Aim of the study was to evaluate the efficacy and safety of sequential intravesical instillations of combined hyaluronic acid (HA) and chondroitin sulfate (CS) in reducing local BCG toxicity and urinary symptoms. Methods This was a prospective, multicentric study. Patients underwent BCG intravesical administration after Transurethral Resection of Bladder Tumor (TURBT) for intermediate/high-risk NMIBC. Patients underwent to HA + CS instillations after every (i) BCG (Group A) were compared with a control group (Group B) that included patient underwent only to BCG instillations, during the maintenance period. 3-day voiding diary, the International Prostate Symptom Score (IPSS), IPSS quality-of-life index (IPSS-QoL), and VAS score (to evaluate bladder pain) were evaluated at baseline and at 1-, 3-, and 6-month follow- up. Results One hundred-eighteen patients were included (Group A: 63 patients, Group B: 55 patients). Mean value of IPSS, IPSS-QoL, and VAS score has significantly increase in Group A at 1-, 3-, and 6-month follow-up (p < 0.00). Group A showed also a significant improvement about irritative lower urinary symptoms (LUTS), which was maintained in the 6-month follow-up, as opposed to Group B that demonstrated a worsening in urinary symptoms during all follow-up (p < 0.00). No local or major side effects were reported during or after treatment. Conclusion This study demonstrated that adding (i) HA + CS significantly reduces storage symptoms, pelvic pain, and day-time urinary frequency in patients with BCG-induced chemical cystitis. This therapy could therefore improve patient adherence, ensuring better adherence and lower drop-out rates.
- Open Access
Efficacy and Safety of a Natural Supplement Containing Serenoa Repens, Solanum Lycopersicum, Lycopene, and Bromelain in Reducing Symptoms of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Prospective Cohort Study in 250 Patients
Background: Chronic Prostatitis/Chronic Pelvic Pain syndrome NIH-class III is a widespread condition affecting men universally, with existing treatments showing limited success. This study evaluated the efficacy and safety of a natural supplement, composed of Serenoa repens, Solanum lycopersicum, lycopene, and bromelain, in managing symptoms of this condition among a substantial patient group. Methods: In this prospective study, 245 patients diagnosed with Chronic Prostatitis/Chronic Pelvic Pain syndrome NIH-class III were treated with the aforementioned supplement, alongside lifestyle alterations, such as refraining from spicy foods, alcohol, caffeine, and cycling, for a duration of three months. Patients’ progress was assessed at one and three months using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), the International Prostate Symptom Index (IPSS), quality of life (QoL) scores, and changes in total prostate-specific antigen (PSA) levels. Results: The supplement was well received with no serious adverse events reported. Significant improvements were observed in NIH-CPSI scores, IPSS, QoL scores, and a substantial decrease in total PSA levels at three months compared to baseline, with a positive trend noted from one-month to three-month evaluations. This was consistent in either patients with predominantly voiding or storage urinary symptoms. Conclusions: Our results suggest that this natural supplement in conjunction with lifestyle changes could offer a safe and effective alternative treatment for patients suffering from Chronic Prostatitis/Chronic Pelvic Pain syndrome NIH-class III. However, these findings require validation through further large-scale randomized controlled trials.
Open AccessEfficacy and Safety of a Natural Supplement Containing Serenoa Repens, Solanum Lycopersicum, Lycopene, and Bromelain in Reducing Symptoms of Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Prospective Cohort Study in 250 Patients
Background: Chronic Prostatitis/Chronic Pelvic Pain syndrome NIH-class III is a widespread condition affecting men universally, with existing treatments showing limited success. This study evaluated the efficacy and safety of a natural supplement, composed of Serenoa repens, Solanum lycopersicum, lycopene, and bromelain, in managing symptoms of this condition among a substantial patient group. Methods: In this prospective study, 245 patients diagnosed with Chronic Prostatitis/Chronic Pelvic Pain syndrome NIH-class III were treated with the aforementioned supplement, alongside lifestyle alterations, such as refraining from spicy foods, alcohol, caffeine, and cycling, for a duration of three months. Patients’ progress was assessed at one and three months using the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI), the International Prostate Symptom Index (IPSS), quality of life (QoL) scores, and changes in total prostate-specific antigen (PSA) levels. Results: The supplement was well received with no serious adverse events reported. Significant improvements were observed in NIH-CPSI scores, IPSS, QoL scores, and a substantial decrease in total PSA levels at three months compared to baseline, with a positive trend noted from one-month to three-month evaluations. This was consistent in either patients with predominantly voiding or storage urinary symptoms. Conclusions: Our results suggest that this natural supplement in conjunction with lifestyle changes could offer a safe and effective alternative treatment for patients suffering from Chronic Prostatitis/Chronic Pelvic Pain syndrome NIH-class III. However, these findings require validation through further large-scale randomized controlled trials.
- Open Access
Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence
Introduction: Lymph node (LN) involvement is a crucial determinant of prognosis for patients with bladder cancer, and an accurate staging is of utmost importance to better identify timely and appropriate therapeutic strategies. To improve the accuracy of LN detection, as an alternative to traditional methods such as CT or MRI, 18F-FDG PET/CT has been increasingly used. 18F-FDG PET/CT is also used in post-treatment restaging after neoadjuvant chemotherapy. The aim of this narrative literature review is to provide an overview of the current evidence on the use of 18F-FDG PET/CT in the diagnosis, staging, and restaging of bladder cancer, with a particular focus on its sensitivity and specificity for the detection of LN metastasis. We aim to provide clinicians with a better understanding of 18F-FDG PET/CT’s potential benefits and limitations in clinical practice. Materials and Methods: We designed a narrative review starting from a wide search in the PubMed/MEDLINE and Embase databases, selecting full-text English articles that have examined the sensibility and specificity of PET/CT for nodal staging or restaging after neoadjuvant therapy in patients with bladder cancer. The extracted data were analyzed and synthesized using a narrative synthesis approach. The results are presented in a tabular format, with a summary of the main findings of each study. Results: Twenty-three studies met the inclusion criteria: fourteen studies evaluated 18F-FDG PET/CT for nodal staging, six studies examined its accuracy for restaging after neoadjuvant therapy, and three studies evaluated both applications. To date, the use of F-18 FDG PET/TC for detection of LN metastasis in bladder cancer is controversial and uncertain: some studies showed low accuracy rates, but over the years other studies have reported evidence of high sensitivity and specificity. Conclusions: 18F-FDG PET/CT provides important incremental staging and restaging information that can potentially influence clinical management in MIBC patients. Standardization and development of a scoring system are necessary for its wider adoption. Well-designed randomized controlled trials in larger populations are necessary to provide consistent recommendations and consolidate the role of 18F-FDG PET/CT in the management of bladder cancer patients.
Open AccessAssessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence
Introduction: Lymph node (LN) involvement is a crucial determinant of prognosis for patients with bladder cancer, and an accurate staging is of utmost importance to better identify timely and appropriate therapeutic strategies. To improve the accuracy of LN detection, as an alternative to traditional methods such as CT or MRI, 18F-FDG PET/CT has been increasingly used. 18F-FDG PET/CT is also used in post-treatment restaging after neoadjuvant chemotherapy. The aim of this narrative literature review is to provide an overview of the current evidence on the use of 18F-FDG PET/CT in the diagnosis, staging, and restaging of bladder cancer, with a particular focus on its sensitivity and specificity for the detection of LN metastasis. We aim to provide clinicians with a better understanding of 18F-FDG PET/CT’s potential benefits and limitations in clinical practice. Materials and Methods: We designed a narrative review starting from a wide search in the PubMed/MEDLINE and Embase databases, selecting full-text English articles that have examined the sensibility and specificity of PET/CT for nodal staging or restaging after neoadjuvant therapy in patients with bladder cancer. The extracted data were analyzed and synthesized using a narrative synthesis approach. The results are presented in a tabular format, with a summary of the main findings of each study. Results: Twenty-three studies met the inclusion criteria: fourteen studies evaluated 18F-FDG PET/CT for nodal staging, six studies examined its accuracy for restaging after neoadjuvant therapy, and three studies evaluated both applications. To date, the use of F-18 FDG PET/TC for detection of LN metastasis in bladder cancer is controversial and uncertain: some studies showed low accuracy rates, but over the years other studies have reported evidence of high sensitivity and specificity. Conclusions: 18F-FDG PET/CT provides important incremental staging and restaging information that can potentially influence clinical management in MIBC patients. Standardization and development of a scoring system are necessary for its wider adoption. Well-designed randomized controlled trials in larger populations are necessary to provide consistent recommendations and consolidate the role of 18F-FDG PET/CT in the management of bladder cancer patients.
- Open Access
- 9 May 2023
- Published by Elsevier in Continence
- Vol. 6
Functional outcomes of mid-urethral tapes in female neurogenic stress and mixed urinary incontinence: A single centre experience
- 9 May 2023
- Published by Elsevier in Continence
- Vol. 6
Open AccessFunctional outcomes of mid-urethral tapes in female neurogenic stress and mixed urinary incontinence: A single centre experience